<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>334</serviceExecutionTime><Drug id="65953"><DrugName>ALX-0171</DrugName><DrugSynonyms><Name><Value>ALX-0171</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>anti-RSV nanobody (inhaled), Ablynx</Value></Name><Name><Value>nanobody (inhaled, RSV infection/pulmonary disease), Ablynx</Value></Name><Name><Value>VR-465</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="31338">Ablynx NV</CompanyOriginator><CompaniesSecondary><Company id="1022734">Activaero GmbH</Company><Company id="29998">Vectura Group plc</Company><Company id="31338">Ablynx NV</Company></CompaniesSecondary><CrossReferences><SourceEntity id="65953" type="Drug"><TargetEntity id="690191" type="siDrug">ALX-0171</TargetEntity></SourceEntity><SourceEntity id="1022734" type="Company"><TargetEntity id="5000471041" type="organizationId">Vectura GmbH</TargetEntity></SourceEntity><SourceEntity id="29998" type="Company"><TargetEntity id="4295898934" type="organizationId">Vectura Group PLC</TargetEntity></SourceEntity><SourceEntity id="31338" type="Company"><TargetEntity id="4296991438" type="organizationId">Ablynx NV</TargetEntity></SourceEntity><SourceEntity id="283" type="ciIndication"><TargetEntity id="10025082" type="MEDDRA"/><TargetEntity id="D008171" type="MeSH"/><TargetEntity id="-1582153652" type="omicsDisease"/><TargetEntity id="3451" type="siCondition"/></SourceEntity><SourceEntity id="287" type="ciIndication"><TargetEntity id="10061603" type="MEDDRA"/><TargetEntity id="D018357" type="MeSH"/><TargetEntity id="-1462311917" type="omicsDisease"/><TargetEntity id="866" type="siCondition"/></SourceEntity><SourceEntity id="511" type="ciIndication"><TargetEntity id="10024968" type="MEDDRA"/><TargetEntity id="923" type="siCondition"/></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="9">Paediatric Investigation Plan</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="283">Lung disease</Indication><Indication id="287">Respiratory syncytial virus infection</Indication><Indication id="511">Lower respiratory tract infection</Indication></IndicationsSecondary><ActionsPrimary><Action id="52108">Respiratory syncytial virus protein F modulator</Action></ActionsPrimary><ActionsSecondary><Action id="991">Antiviral</Action></ActionsSecondary><Technologies><Technology id="180">Antibody fragment</Technology><Technology id="267">Multivalent antibody</Technology><Technology id="616">Inhalant formulation</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2019-05-13T06:13:31.000Z</LastModificationDate><ChangeDateLast>2019-05-13T00:00:00.000Z</ChangeDateLast><AddedDate>2010-03-29T10:57:15.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="31338" linkType="Company"&gt;Ablynx&lt;/ulink&gt; (subsidiary of &lt;ulink linkID="1009547" linkType="Company"&gt;Sanofi&lt;/ulink&gt;), in collaboration with &lt;ulink linkID="29998" linkType="Company"&gt;Vectura&lt;/ulink&gt;  following its acquisition of   &lt;ulink linkID="1022734" linkType="Company"&gt;Activaero&lt;/ulink&gt;, was developing ALX-0171 (VR-465), a trivalent, non-half-life extended  nanobody-based inhalation therapeutic that targets RSV protein F, using Vectura's FOX system, for the potential  treatment   of adults diagnosed with respiratory syncytial  virus (RSV)  lower respiratory tract infection after hematopoietic stem cell transplantation and infants hospitalized for a lower respiratory tract RSV infection     [&lt;ulink linkID="1085762" linkType="Reference"&gt;1085762&lt;/ulink&gt;], [&lt;ulink linkID="1306766" linkType="Reference"&gt;1306766&lt;/ulink&gt;], [&lt;ulink linkID="1505420" linkType="Reference"&gt;1505420&lt;/ulink&gt;], [&lt;ulink linkID="1534395" linkType="Reference"&gt;1534395&lt;/ulink&gt;], [&lt;ulink linkID="1621373" linkType="Reference"&gt;1621373&lt;/ulink&gt;], [&lt;ulink linkID="1622849" linkType="Reference"&gt;1622849&lt;/ulink&gt;], [&lt;ulink linkID="1776859" linkType="Reference"&gt;1776859&lt;/ulink&gt;], [&lt;ulink linkID="2019958" linkType="Reference"&gt;2019958&lt;/ulink&gt;], [&lt;ulink linkID="2046132" linkType="Reference"&gt;2046132&lt;/ulink&gt;]. In January 2017, a phase IIb trial was initiated in hospitalized children for respiratory syncytial virus infection. Topline results from the trial were expected by the end of  2018 [&lt;ulink linkID="1891943" linkType="Reference"&gt;1891943&lt;/ulink&gt;]; in October 2018, following the results of  phase IIb  study, Sanofi decided not to pursue further development of the drug in  infant population as the  clinical efficacy was consistent [&lt;ulink linkID="2088643" linkType="Reference"&gt;2088643&lt;/ulink&gt;].  In March 2018,  a phase II study was planned in adults diagnosed with RSV respiratory tract infection after HSCT  [&lt;ulink linkID="2019958" linkType="Reference"&gt;2019958&lt;/ulink&gt;], [&lt;ulink linkID="2088643" linkType="Reference"&gt;2088643&lt;/ulink&gt;]. However, in February 2019, development of the drug was discontinued   [&lt;ulink linkID="2117414" linkType="Reference"&gt;2117414&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Adults diagnosed with lower respiratory tract RSV  infection after HSCT&lt;/subtitle&gt;In August 2017, the company was planning to file to initiate a phase II study in RSV-infected haematopoietic stem cell transplant (HSCT) patients in the first half of 2018 [&lt;ulink linkID="1955924" linkType="Reference"&gt;1955924&lt;/ulink&gt;]. In March 2018, a randomized, double-blind, quadruple, multicenter dose ranging, parallel group,  interventional phase II study (&lt;ulink linkID="332886" linkType="Protocol"&gt;NCT03468829&lt;/ulink&gt;; ALX0171-C204;   2017-003356-23; BREEZE) was planned in the  Belgium to assess the antiviral effect, safety, clinical activity, pharmacokinetics, virology, and immunogenicity  of inhaled ALX-0171   in adults (expected n = 75)  diagnosed with RSV respiratory tract infection after HSCT. The primary endpoint was the time-weighted average change from baseline in log10 RSV nasal viral load. At that time, the trial was to begin in March 2018 and complete in May 2020 [&lt;ulink linkID="2019958" linkType="Reference"&gt;2019958&lt;/ulink&gt;], [&lt;ulink linkID="2088643" linkType="Reference"&gt;2088643&lt;/ulink&gt;]. In March 2019, the trial was withdrawn and development of the drug was discontinued [&lt;ulink linkID="2019958" linkType="Reference"&gt;2019958&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Infants with lower respiratory tract RSV infection&lt;/subtitle&gt;In May 2017, clinical development was expected to be initiated in Japan during 2017 [&lt;ulink linkID="1926492" linkType="Reference"&gt;1926492&lt;/ulink&gt;]. In August 2017, filing to initiate a phase II study in Japanese infants hospitalised with RSV infection was expected in the fourth quarter of 2017 and the study was to commence in the first half of 2018 [&lt;ulink linkID="1955924" linkType="Reference"&gt;1955924&lt;/ulink&gt;]. This was still the case in February 2018 [&lt;ulink linkID="2007283" linkType="Reference"&gt;2007283&lt;/ulink&gt;]. In March 2018, a randomized, sequential-assigned, double-blind, multicenter, placebo-controlled, multiple dose phase II study (&lt;ulink linkID="327807" linkType="Protocol"&gt;NCT03418571&lt;/ulink&gt;; ALX0171-C203) to evaluate the safety, tolerability, and systemic pharmacokinetics, antiviral effect, clinical activity, immunogenicity, and pharmacodynamics of different doses of ALX-0171 in Japanese infants and young children (expected n = 60) hospitalized for respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) was initiated in Japan. The primary endpoint was to determine the safety and tolerability by the incidence of treatment-emergent (serious) adverse events. At that time, the trial was expected to complete in May 2019 [&lt;ulink linkID="2042940" linkType="Reference"&gt;2042940&lt;/ulink&gt;]. Later that month, a total of four doses were to be assessed and a safety review by an independent Data Monitoring Committee was planned prior to initiating each new dose. Patients were to received ALX-0171 once-daily for three days plus standard-of-care treatment.   At that time, data were expected in 2H19 [&lt;ulink linkID="2009865" linkType="Reference"&gt;2009865&lt;/ulink&gt;]. In October 2018, following the results of  phase IIb  RESPIRE study, Sanofi decided not to pursue further development of the drug in  infant population [&lt;ulink linkID="2088643" linkType="Reference"&gt;2088643&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015, Ablynx planned to initiate a global phase IIb study in more than 150 infants, in late 2016 [&lt;ulink linkID="1661602" linkType="Reference"&gt;1661602&lt;/ulink&gt;]. In June 2016, the  phase IIb dose-ranging study was 'forthcoming' [&lt;ulink linkID="1776859" linkType="Reference"&gt;1776859&lt;/ulink&gt;]. In August 2016, a randomized, double-blind, placebo-controlled, multicenter dose ranging, interventional phase IIb study (&lt;ulink linkID="281014" linkType="Protocol"&gt;NCT02979431&lt;/ulink&gt;;&lt;ulink linkID="281014" linkType="Protocol"&gt; 2016-001651-49&lt;/ulink&gt;: ALX0171-C201; RESPIRE) was planned to asses the safety and efficacy of ALX-0171 in infants and young hospitalized children  (expected n = 180) for respiratory syncytial virus infection lower respiratory tract infection. At that time, the study was  to begin in the fourth quarter of 2016  and  complete in September 2018 [&lt;ulink linkID="1872748" linkType="Reference"&gt;1872748&lt;/ulink&gt;], [&lt;ulink linkID="1906470" linkType="Reference"&gt;1906470&lt;/ulink&gt;].  [&lt;ulink linkID="1791073" linkType="Reference"&gt;1791073&lt;/ulink&gt;]. In September 2016, the trial was expected to begin in 2016 or in the first half of 2017 [&lt;ulink linkID="1803859" linkType="Reference"&gt;1803859&lt;/ulink&gt;]. In November 2016, the trial was expected to be initiated by the end of 2016 [&lt;ulink linkID="1877619" linkType="Reference"&gt;1877619&lt;/ulink&gt;]. In January 2017, the first patient was dosed in the international, cohort, sequential dose escalation trial. At that time, patient recruitment was expected to be completed in first half of 2018 and topline results were expected by the end of 2018  [&lt;ulink linkID="1891943" linkType="Reference"&gt;1891943&lt;/ulink&gt;]. By January 2017, the study had been initiated in Belgium, Hungary and Spain [&lt;ulink linkID="1906470" linkType="Reference"&gt;1906470&lt;/ulink&gt;]. In May 2017, topline results were expected in the second half of 2018 [&lt;ulink linkID="1926492" linkType="Reference"&gt;1926492&lt;/ulink&gt;]. By August 2017, sequential dose escalation part of the study had been completed in 36 infants and the parallel dose exploration part was initiated with the aim of recruiting an additional 144 infants after a positive recommendation from the Data Monitoring Committee [&lt;ulink linkID="1955924" linkType="Reference"&gt;1955924&lt;/ulink&gt;]. In March 2018, topline data from the trial were expected in fourth quarter of 2018 [&lt;ulink linkID="2015844" linkType="Reference"&gt;2015844&lt;/ulink&gt;]. In April 2018, recruitment was completed with 180 infants enrolled in the trial. At that time, data were expected to be reported in the second half of 2018 [&lt;ulink linkID="2028721" linkType="Reference"&gt;2028721&lt;/ulink&gt;]. By October 2018, following the results of the phase IIb  study, Sanofi decided not to pursue further development  in the infant population. Though results were positive for the primary endpoint of anti-viral efficacy and target exposure was achieved, consistent clinical efficacy was not observed across secondary endpoints [&lt;ulink linkID="2088643" linkType="Reference"&gt;2088643&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2013 at the 31st Annual JPMorgan Healthcare Conference in San Francisco, CA, it was reported that a phase II study in infants had the potential to start in 2014 [&lt;ulink linkID="1356874" linkType="Reference"&gt;1356874&lt;/ulink&gt;]. In July 2013, the trial was expected to begin in second half of 2014 [&lt;ulink linkID="1448097" linkType="Reference"&gt;1448097&lt;/ulink&gt;]. In May 2014, the proof-of-concept pediatric phase IIa trial was expected to be initiated in the fourth quarter of 2014 and data were expected in 2015 [&lt;ulink linkID="1553386" linkType="Reference"&gt;1553386&lt;/ulink&gt;], [&lt;ulink linkID="1611715" linkType="Reference"&gt;1611715&lt;/ulink&gt;]. In September 2014, the European Medicines Agency approved the pediatric investigation plan for ALX-0171. In November 2014, the phase I/IIa study was expected to be completed in September 2015. In December 2014, recruitment was initiated in the two-part, multicenter, multi-country trial (&lt;ulink linkID="217597" linkType="Protocol"&gt;NCT02309320&lt;/ulink&gt;; ALX00171-C104, 2014-002841-23) to evaluate the safety, tolerability and clinical activity of ALX-0171 in healthy infants and toddlers (expected n = 35) diagnosed with RSV and hospitalized for a lower respiratory tract infection, in five European countries. The first part of the study would be an open-label "lead-in" part to assess the safety of ALX-0171 in five patients. After a positive recommendation following a review of safety data by an independent data monitoring committee, 30 patients were to be enrolled in the subsequent double-blind, randomized, placebo-controlled part of the study. At that time, the study was expected to be completed in the second quarter of 2015 and data were expected in the third quarter of 2015 [&lt;ulink linkID="1621373" linkType="Reference"&gt;1621373&lt;/ulink&gt;], [&lt;ulink linkID="1621388" linkType="Reference"&gt;1621388&lt;/ulink&gt;]. By May 2015, the lead part of the trial with five infants had been completed. At that time, the study was enrolling 30 infants for the placebo-controlled part of the trial and the enrollment was expected to complete by the end of 2015 with  results expected in the first half of 2016 [&lt;ulink linkID="1657603" linkType="Reference"&gt;1657603&lt;/ulink&gt;]. By that time, enrollment of 30 patients had been ongoing in the northern hemisphere, and was expected to begin  in Asia Pacific region [&lt;ulink linkID="1659324" linkType="Reference"&gt;1659324&lt;/ulink&gt;]. In October 2015, the trial was underway in Australia, Belgium, Hungary, Malaysia, Slovakia, Spain, Thailand, and the UK, and at that time, the study was expected to complete in December 2015 [&lt;ulink linkID="1621388" linkType="Reference"&gt;1621388&lt;/ulink&gt;]. In November 2015, the company was planning to publish the results from the trial in the first half of 2016 [&lt;ulink linkID="1714433" linkType="Reference"&gt;1714433&lt;/ulink&gt;]. In December 2015, the trial had completed  target enrollment and following a  positive recommendation from an independent Data Monitoring Committee (DMC) based on the data from 15 infants from the placebo-controlled part of the trial, the age requirement in the trial had been reduced from 3 months to 1 month. The trial would continue with an expansion cohort enrolling younger infants aged 1 to 5 months. Results from the extension part would be available in the second half of 2016  [&lt;ulink linkID="1722273" linkType="Reference"&gt;1722273&lt;/ulink&gt;]. In March 2016, the trial was completed in Thailand, Philippines and Israel [&lt;ulink linkID="1621388" linkType="Reference"&gt;1621388&lt;/ulink&gt;]. In May 2016, top-line results from the first-in-infant, phase I/IIa trial in 53 hospitalized RSV-infected infants were reported. ALX-0171 was safe and well tolerated. Data demonstrated that the study met its primary endpoint of favourable safety and tolerability profile of ALX-0171 when administered daily by inhalation. Also, inhaled ALX-0171 showed an immediate impact on viral replication and also reduced viral load, as compared to placebo. Furthermore, analysis of a composite of clinical efficacy endpoints, the Global Severity Score, led to an encouraging initial indication of a therapeutic effect for infants treated with ALX-0171 [&lt;ulink linkID="1758307" linkType="Reference"&gt;1758307&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;&lt;subtitle&gt;Other Lung diseases&lt;/subtitle&gt;In January 2013, it was reported at the 31st Annual JPMorgan Healthcare Conference in San Francisco, CA, that a local and systemic pharmacokinetic study in healthy subjects was planned; results were expected in 1H 2014 [&lt;ulink linkID="1356874" linkType="Reference"&gt;1356874&lt;/ulink&gt;]. In July 2013, a phase I trial in  healthy subjects (n = 41) to assess  local and systemic pharmacokinetics of single and repeated daily inhalations (200 mg) and of single iv ALX-0171 (0.3 mg/kg) was initiated [&lt;ulink linkID="1448097" linkType="Reference"&gt;1448097&lt;/ulink&gt;]. In May 2014, results were reported that ALX-0171 rapidly attained clinically relevant levels after once-daily administration by inhalation and the drug was well tolerated [&lt;ulink linkID="1553386" linkType="Reference"&gt;1553386&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2013, it was reported at the 31st Annual JPMorgan Healthcare Conference in San Francisco, CA, that a study was planned to assess safety in asthmatic patients; results were expected in 1H 2014 [&lt;ulink linkID="1356874" linkType="Reference"&gt;1356874&lt;/ulink&gt;]. In July 2013, a single-center, open-label phase I trial in adults (n = 24) with hyper responsive airways was to assess the potential occurrence of bronchoconstriction  and to determine the dosing regimen for paediatric trial with single-escalating doses and repeated inhalation of  ALX-0171 was initiated [&lt;ulink linkID="1448097" linkType="Reference"&gt;1448097&lt;/ulink&gt;]. In May 2014, results were reported that ALX-0171 was found to be safe and well tolerated [&lt;ulink linkID="1553386" linkType="Reference"&gt;1553386&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2011, a single-centre, single- and multiple-dose, randomized, placebo-controlled phase I trial (&lt;ulink linkID="82945" linkType="Protocol"&gt;NCT01483911&lt;/ulink&gt;) was initiated  in healthy volunteers (expected n = 60), to  assess the safety, tolerability and pharmacokinetic  profile of ALX-0171. The single ascending dose part was to include six dose levels and recruit 44 subjects, and would be followed by a multiple dose part in 16 subjects. At that time, results were expected in the third quarter   of 2012 [&lt;ulink linkID="1247979" linkType="Reference"&gt;1247979&lt;/ulink&gt;]; in September 2012, results from the trial were reported data demonstrated that the drug was safe and tolerable [&lt;ulink linkID="1324138" linkType="Reference"&gt;1324138&lt;/ulink&gt;]. In January 2013, similar data were presented at the 31st Annual JPMorgan Healthcare Conference in San Francisco, CA [&lt;ulink linkID="1356874" linkType="Reference"&gt;1356874&lt;/ulink&gt;]. In May 2013,  data from the double-blind study were presented at the AAPS National Biotech Conference in San Diego, CA. Healthy male subjects received ALX-0171 at doses of 2.1 to 210 mg in the single ascending dose study (n = 32) and 70 or 105 mg bid for 5 days in the multiple dose study (n = 12) via inhalation (flow rate: 15 l/min). In the serum ADA assay (systemic immunogenicity), 5% of ALX-0171 recipients (2/44) were positive at &amp;gt;/= 1 time points. In the induced sputum ADA assay (local immunogenicity), 4% of ALX-0171 recipients (1/32) tested positive at pre-dose alone. Treatment-emergent ADA responses were not observed, indicating no increase in titer [&lt;ulink linkID="1464411" linkType="Reference"&gt;1464411&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2019, in vivo data were presented at the 2019 Experimental Biology Annual Meeting in Orlando, FL. In lambs, ALX-0171 (0, 1.4, 2.8 and 11 mg) delivered by nebulization at 3, 4, and 5 days after infection with a human strain of RSV (Memphis 37 strain) led to no  lesions at 2 days post RSV infection, and had reduced lesions and viral parameters at 4 and 6 days post RSV infection compared to lesions in lambs not receiving treatment [&lt;ulink linkID="2138095" linkType="Reference"&gt;2138095&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015, preclinical data were presented at the 2015 ATS International Conference in Denver, CO.										In colostrum-deprived newborn lambs nebulized with RSV-M37,  inhalation of ALX-0171  improved the general well-being of the lambs compared with vehicle-treated lambs.  ALX-0171 treatment showed a positive effect on clinical parameters (respiratory rates, wheeze, expiratory efforts, temperature, malaise and body weights) of the lambs and was well-tolerated [&lt;ulink linkID="1679878" linkType="Reference"&gt;1679878&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015, preclinical data were presented at the Respiratory Drug Delivery (RDD) Europe 2015 Conference, held in Nice, France. In vitro data demonstrated that, the inhaled nanobody, ALX-0171, was directly  delivered to the site of viral infection and inhibited viral replication and also neutralized viral activity by blocking viral uptake in the cells [&lt;ulink linkID="1657603" linkType="Reference"&gt;1657603&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2014, preclinical data were presented at SMI's third Annual ADC Summit in London, UK. ALX-0171 demonstrated approximately 7000-fold improved potency when compared to the natural antibody and increased strain coverage [&lt;ulink linkID="1562306" linkType="Reference"&gt;1562306&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2013, preclinical data reported that ALX-0171 had significantly deposited in the reconstructed upper airway anatomical model of a 9-month old baby lung [&lt;ulink linkID="1494385" linkType="Reference"&gt;1494385&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2013, preclinical data were presented at the AAPS National Biotech Conference in San Diego, CA. In  Crl: CD rats following the administration of ALX-0171 (0 to 117 mg/kg/day), the plasma AUC (0 to 24 h) values were 1749 and 4506 ng.h/ml on days 1 and 14, respectively. Plasma concentration increased with dose (47 to 68 ng/ml) after single dose inhalation. In pharmacokinetic analysis, a moderate systemic exposure was observed with an absolute bioavailability of 10% after aerosol administration. ALX-0171 was well tolerated [&lt;ulink linkID="1464535" linkType="Reference"&gt;1464535&lt;/ulink&gt;]. Later that month, further data were presented at the same conference.  Treatment-emergent anti-drug antibody (ADA) levels were detectable in the plasma of 5/44, 8/44 and 17/54 Crl: CD Sprague Dawley rats that received ALX-0171 at doses of 17, 42 and 117 mg/kg, respectively, via nebulization for 14 days. ADA levels were detectable in the bronchioalveolar fluid of one of the six rats that received ALX-0171(42 mg/kg) via nebulization [&lt;ulink linkID="1464411" linkType="Reference"&gt;1464411&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 2013, it was reported at the 31st Annual JPMorgan Healthcare Conference in San Francisco, CA, that further preclinical studies would be carried out including juvenile animals studies to extend  pharmacokinetic knowledge, inflammatory/histopathological studies in human infant lung 3-D epithelial cell cultures, and an in vivo neonatal lamb efficacy study [&lt;ulink linkID="1356874" linkType="Reference"&gt;1356874&lt;/ulink&gt;]. By May 2013, a pre-clinical study in juvenile animals had been initiated and first results were expected by the end of 2013 [&lt;ulink linkID="1421163" linkType="Reference"&gt;1421163&lt;/ulink&gt;]. By February 2014, proof-of-concept  data had demonstrated that in a neonatal lamb model, daily inhalation of ALX-0171 resulted in a reduction of viral titres and lung inflammation, and was effective in alleviating various clinical signs and symptoms [&lt;ulink linkID="1529442" linkType="Reference"&gt;1529442&lt;/ulink&gt;]. In November 2014, similar data from the neonatal lamb model of RSV infection were expected to be presented at the 9th International Respiratory Syncytial Virus (RSV) Symposium,  to be held in Stellenbosch, South Africa. The drug reduced the viral titres by greater than 10,000-fold, after once-daily inhalation for three consecutive days [&lt;ulink linkID="1609040" linkType="Reference"&gt;1609040&lt;/ulink&gt;]; in May 2015, similar data were presented at the Respiratory Drug Delivery (RDD) Europe 2015 Conference, held in Nice, France [&lt;ulink linkID="1657603" linkType="Reference"&gt;1657603&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2012, preclinical data were presented at the SMR's Respiratory Drug Discovery, Current Developments and Future Challenges in Horsham, UK. In a plaque reduction assay with 61 recently isolated RSV clinical strains, ALX-0171 (40 mg/ml) reduced viral replication below the limit of detection more efficiently than &lt;ulink linkID="8747" linkType="Drug"&gt;palivizumab&lt;/ulink&gt; (84% versus 20% of strains, respectively). ALX-0171 was shown to be effective in vivo in a therapeutic RSV cotton rat model. A 2-week repeated-dose toxicity study by nebulization was conducted in rats, achieving maximal feasible dose levels without DLT [&lt;ulink linkID="1306766" linkType="Reference"&gt;1306766&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;  In October 2011, the therapy was listed as being in preclinical testing for  pulmonary diseases [&lt;ulink linkID="1269342" linkType="Reference"&gt;1269342&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By March 2010, the drug had been shown to be effective for the prevention and treatment of RSV in  vivo models [&lt;ulink linkID="1085762" linkType="Reference"&gt;1085762&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In August 2014, the EMA's Pediatric Committee (PDCO) adopted an opinion agreeing a pediatric investigation plan (PIP) for the drug for RSV infection [&lt;ulink linkID="1592783" linkType="Reference"&gt;1592783&lt;/ulink&gt;]. In December 2016, the EMA's Pediatric Committee adopted a positive opinion on modifications to the PIP for ALX-0171 for RSV infection [&lt;ulink linkID="1893809" linkType="Reference"&gt;1893809&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; &lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="31338">Ablynx NV</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="511">Lower respiratory tract infection</Indication><StatusDate>2019-02-07T00:00:00.000Z</StatusDate><Source id="2117414" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="31338">Ablynx NV</Company><Country id="MY">Malaysia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="511">Lower respiratory tract infection</Indication><StatusDate>2019-02-07T00:00:00.000Z</StatusDate><Source id="2117414" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="31338">Ablynx NV</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="287">Respiratory syncytial virus infection</Indication><StatusDate>2019-02-07T00:00:00.000Z</StatusDate><Source id="2117414" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="31338">Ablynx NV</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="511">Lower respiratory tract infection</Indication><StatusDate>2019-02-07T00:00:00.000Z</StatusDate><Source id="2117414" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="31338">Ablynx NV</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="511">Lower respiratory tract infection</Indication><StatusDate>2019-02-07T00:00:00.000Z</StatusDate><Source id="2117414" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="31338">Ablynx NV</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="511">Lower respiratory tract infection</Indication><StatusDate>2019-02-07T00:00:00.000Z</StatusDate><Source id="2117414" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="31338">Ablynx NV</Company><Country id="TH">Thailand</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="511">Lower respiratory tract infection</Indication><StatusDate>2019-02-07T00:00:00.000Z</StatusDate><Source id="2117414" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="31338">Ablynx NV</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="287">Respiratory syncytial virus infection</Indication><StatusDate>2019-02-07T00:00:00.000Z</StatusDate><Source id="2117414" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="31338">Ablynx NV</Company><Country id="TH">Thailand</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="287">Respiratory syncytial virus infection</Indication><StatusDate>2019-02-07T00:00:00.000Z</StatusDate><Source id="2117414" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="31338">Ablynx NV</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="287">Respiratory syncytial virus infection</Indication><StatusDate>2019-02-07T00:00:00.000Z</StatusDate><Source id="2117414" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="31338">Ablynx NV</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="287">Respiratory syncytial virus infection</Indication><StatusDate>2019-02-07T00:00:00.000Z</StatusDate><Source id="2117414" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="31338">Ablynx NV</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="287">Respiratory syncytial virus infection</Indication><StatusDate>2019-02-07T00:00:00.000Z</StatusDate><Source id="2117414" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="31338">Ablynx NV</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="511">Lower respiratory tract infection</Indication><StatusDate>2019-02-07T00:00:00.000Z</StatusDate><Source id="2117414" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29998">Vectura Group plc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="287">Respiratory syncytial virus infection</Indication><StatusDate>2019-02-07T00:00:00.000Z</StatusDate><Source id="2117414" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="31338">Ablynx NV</Company><Country id="MY">Malaysia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="287">Respiratory syncytial virus infection</Indication><StatusDate>2019-02-07T00:00:00.000Z</StatusDate><Source id="2117414" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="31338">Ablynx NV</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="287">Respiratory syncytial virus infection</Indication><StatusDate>2010-03-26T00:00:00.000Z</StatusDate><Source id="1085762" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1022734">Activaero GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="287">Respiratory syncytial virus infection</Indication><StatusDate>2013-12-03T00:00:00.000Z</StatusDate><Source id="1505420" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="31338">Ablynx NV</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="287">Respiratory syncytial virus infection</Indication><StatusDate>2011-12-13T00:00:00.000Z</StatusDate><Source id="1247979" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="31338">Ablynx NV</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="287">Respiratory syncytial virus infection</Indication><StatusDate>2017-05-11T00:00:00.000Z</StatusDate><Source id="1926492" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="31338">Ablynx NV</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="283">Lung disease</Indication><StatusDate>2011-10-11T00:00:00.000Z</StatusDate><Source id="1269342" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="31338">Ablynx NV</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="287">Respiratory syncytial virus infection</Indication><StatusDate>2018-03-02T00:00:00.000Z</StatusDate><Source id="2009865" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="31338">Ablynx NV</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="287">Respiratory syncytial virus infection</Indication><StatusDate>2016-03-15T00:00:00.000Z</StatusDate><Source id="1621388" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="31338">Ablynx NV</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="287">Respiratory syncytial virus infection</Indication><StatusDate>2016-03-15T00:00:00.000Z</StatusDate><Source id="1621388" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="31338">Ablynx NV</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="287">Respiratory syncytial virus infection</Indication><StatusDate>2014-12-17T00:00:00.000Z</StatusDate><Source id="1621373" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29998">Vectura Group plc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="287">Respiratory syncytial virus infection</Indication><StatusDate>2014-03-13T00:00:00.000Z</StatusDate><Source id="1534395" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="31338">Ablynx NV</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="287">Respiratory syncytial virus infection</Indication><StatusDate>2014-11-30T00:00:00.000Z</StatusDate><Source id="1621388" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="31338">Ablynx NV</Company><Country id="MY">Malaysia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="287">Respiratory syncytial virus infection</Indication><StatusDate>2014-11-30T00:00:00.000Z</StatusDate><Source id="1621388" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="31338">Ablynx NV</Company><Country id="TH">Thailand</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="287">Respiratory syncytial virus infection</Indication><StatusDate>2014-11-30T00:00:00.000Z</StatusDate><Source id="1621388" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="31338">Ablynx NV</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="511">Lower respiratory tract infection</Indication><StatusDate>2016-03-15T00:00:00.000Z</StatusDate><Source id="1621388" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="31338">Ablynx NV</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="511">Lower respiratory tract infection</Indication><StatusDate>2016-03-15T00:00:00.000Z</StatusDate><Source id="1621388" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="31338">Ablynx NV</Company><Country id="TH">Thailand</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="511">Lower respiratory tract infection</Indication><StatusDate>2014-11-30T00:00:00.000Z</StatusDate><Source id="1621388" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="31338">Ablynx NV</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="511">Lower respiratory tract infection</Indication><StatusDate>2018-03-02T00:00:00.000Z</StatusDate><Source id="2009865" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="31338">Ablynx NV</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="511">Lower respiratory tract infection</Indication><StatusDate>2014-12-17T00:00:00.000Z</StatusDate><Source id="1621373" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="31338">Ablynx NV</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="511">Lower respiratory tract infection</Indication><StatusDate>2014-11-30T00:00:00.000Z</StatusDate><Source id="1621388" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="31338">Ablynx NV</Company><Country id="MY">Malaysia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="511">Lower respiratory tract infection</Indication><StatusDate>2014-11-30T00:00:00.000Z</StatusDate><Source id="1621388" type="TRIALREG"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="9">Paediatric Investigation Plan</RegulatoryDesignation><OwnerCompany id="31338">Ablynx NV</OwnerCompany><Country id="EU">EU</Country><Indication id="287">Respiratory syncytial virus infection</Indication><AwardedIndication>Respiratory syncytial virus infection</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2017-01-17T00:00:00.000Z</MileStoneDate><Source id="1893809" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-09443"><Name>Respiratory syncytial virus protein F</Name><SwissprotNumbers><Swissprot>P03420</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2137767" linkType="reference" linkID="2137767"&gt;2137767&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1009547">Sanofi SA</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>4</CountTotal></Company><Company><Company id="1042808">Institute for the Promotion of Innovation by Science and Technology in Flanders</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="19222">Research Corporation Technologies</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="29998">Vectura Group plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="12">Patent - Non-Exclusive Rights</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="8">Technology - Delivery/Formulation</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="128743" title="IWT to fund Ablynx for development of alternative routes of administration for Nanobodies "/><Deal id="147624" title="Ablynx and Activaero to codevelop ALX-0171 for the treatment of respiratory syncytial virus infection worldwide "/><Deal id="161205" title="Ablynx to acquire an option to license Vectura's FOX device for delivery of ALX-0171 against RSV              "/><Deal id="245711" title="Ablynx to use RCT's IP related to strains of Pichia pastoris technology  to produce nanobody products used in ALX-0171 and vobarilizumab worldwide"/></Deals><PatentFamilies><PatentFamily id="1787532" number="WO-2011064382" title="Improved amino acid sequences directed against human respiratory syncytial virus (hRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections"/><PatentFamily id="2915101" number="WO-2015049519" title="Method and apparatus"/><PatentFamily id="3166094" number="WO-2016055655" title="Inhalation device for use in aerosol therapy of respiratory diseases"/><PatentFamily id="3363669" number="WO-2010139808" title="Improved amino acid sequences directed against human respiratory syncytial virus (hRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections"/><PatentFamily id="3840726" number="WO-2017191108" title="Treatment of RSV infection"/><PatentFamily id="3894648" number="WO-2017220645" title="Improved pharmacokinetic assays for immunoglobulin single variable domains"/><PatentFamily id="4080857" number="WO-2018099968" title="Treatment of infection by respiratory syncytial virus (RSV)"/><PatentFamily id="78543" number="WO-2011098552" title="Methods and compositions for the preparation of aerosols"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="4">Delivery device</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"/><CountAsOwner>7</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>7</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AgroSavfe NV" id="1081487"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AmatsiGroup" id="1137408"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Orionis Biosciences NV" id="1147708"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Antwerp" id="22741"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="GlaxoSmithKline plc" id="28355"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Vectura Group plc" id="29998"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>